Conclusion
toxicity
In order to improve therapeutic outcomes for patients with A/R/M HNSCC, we aim to assess response to, survival associated with and toxicity of a novel combination of pembrolizumab and QS RT. Extensive laboratory correlative analyses are planned to elucidate the immune-related impact of this RT regimen combined with ICI. Additionally, the data provided by this clinical trial may provide evidence supporting future confirmatory clinical trials investigating this paradigm.